Anne Altmeyer

Anne Altmeyer, PhD, MBA, MPH, currently serves as Chief Executive Officer at TigaTx, focusing on harnessing the tumor-killing potential of engineered IgA neutrophils. In addition to this role, Altmeyer holds the position of Director at Corbus Pharmaceuticals. Previously, significant leadership roles included Chief Business Officer at both Sigilon Therapeutics, Inc. and Adicet Bio, Inc., and Vice President of Business Development and Negotiations at Baxalta, overseeing key negotiations in several therapeutic areas including Hematology and Oncology. Altmeyer's extensive career at Novartis spanned over a decade with various titles including Vice President of Business Development & Licensing and Executive Director in Oncology. Early career experiences include project management roles at Merck & Co., along with research and fellowship positions at Cornell University Medical College and New York University Medical Center. Altmeyer earned a PhD from Université Louis Pasteur, an MBA from Rutgers Business School, and an MPH from the University of Medicine and Dentistry of New Jersey, along with education from The Wharton School.